CORCEPT THERAPEUTICS INC
CORCEPT THERAPEUTICS INC (CORT): 7 pipeline candidates · ~63 mo cash runway · 18 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
63.3 months
D/E 0.28
Lead: Approved
7 candidates
N/A
2 buys · 16 sells (180d)
A transparent, data-derived signal for CORCEPT THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$9.0B
Cash
$110.0M
Quarterly Burn
$16.8M
Runway
63.3 mo
Revenue
$164.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| dazucorilant | Phase 1 |
| exicorilant | Phase 1/Phase 2 |
| itraconazole | Phase 1 |
| korlym | Approved |
| miricorilant | Phase 1 |
| nenocorilant | Phase 1/Phase 2 |
| relacorilant | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
348
Total value held
$2.98B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,151,276 | $489.8M |
| vanguard capital management llc | 8,154,392 | $328.7M |
| renaissance technologies llc | 5,682,783 | $229.1M |
| vanguard portfolio management llc | 4,820,568 | $194.3M |
| state street corp | 3,200,946 | $129.0M |
| fmr llc | 3,190,192 | $128.6M |
| geode capital management, llc | 2,713,519 | $109.4M |
| first trust advisors lp | 2,173,376 | $87.6M |
| dimensional fund advisors lp | 1,553,135 | $62.6M |
| tang capital management llc | 1,500,000 | $60.5M |
Showing top 10 of 348 institutional holders of CORCEPT THERAPEUTICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CORCEPT THERAPEUTICS INC's pipeline?
CORCEPT THERAPEUTICS INC (CORT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CORCEPT THERAPEUTICS INC's lead drug candidate?
CORCEPT THERAPEUTICS INC's most advanced tracked candidate is dazucorilant (Phase 1) for Hepatic Impairment; Amyotrophic Lateral Sclerosis; Healthy Adults.
What is CORCEPT THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CORCEPT THERAPEUTICS INC has approximately 63.3 months of cash runway.
What is CORCEPT THERAPEUTICS INC's market capitalization?
CORCEPT THERAPEUTICS INC's market capitalization is approximately $9.0B.
Who is the CEO of CORCEPT THERAPEUTICS INC?
Dr. Joseph K. Belanoff M.D. is the chief executive officer of CORCEPT THERAPEUTICS INC (CORT).
Get the full picture on CORCEPT THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.